950210 — Prestige Biopharma Share Price
- KR₩5tn
- KR₩5tn
- $0.52m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 12.68 | ||
Price to Tang. Book | 19.17 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2,180.77 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -11.1% | ||
Return on Equity | -8.97% | ||
Operating Margin | -2725.55% |
Financial Summary
Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | 0.12 | 0.52 | n/a | n/a | -22.42% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008, and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and antitumor growth effects. IDC001 is designed to treat cancers that have high levels of PAUF and CTHRC1.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- July 13th, 2015
- Public Since
- February 5th, 2021
- No. of Shareholders
- 36,723
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE
- Shares in Issue
- 72,115,386

- Address
- 21 Biopolis Road, 138567
- Web
- https://www.prestigebiopharma.com/
- Phone
- +65 69246535
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 950210
Similar to 950210
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 04:43 UTC, shares in Prestige Biopharma are trading at KR₩14,650. This share price information is delayed by 15 minutes.
Shares in Prestige Biopharma last closed at KR₩14,650 and the price had moved by +84.07% over the past 365 days. In terms of relative price strength the Prestige Biopharma share price has outperformed the FTSE Developed Asia Pacific Index by +87.5% over the past year.
The overall consensus recommendation for Prestige Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePrestige Biopharma does not currently pay a dividend.
Prestige Biopharma does not currently pay a dividend.
Prestige Biopharma does not currently pay a dividend.
To buy shares in Prestige Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩14,650, shares in Prestige Biopharma had a market capitalisation of KR₩5tn.
Here are the trading details for Prestige Biopharma:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 950210
Based on an overall assessment of its quality, value and momentum Prestige Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Prestige Biopharma is KR₩30,000. That is 104.78% above the last closing price of KR₩14,650.
Analysts covering Prestige Biopharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prestige Biopharma. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +9.83%.
As of the last closing price of KR₩14,650, shares in Prestige Biopharma were trading +15.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Prestige Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩14,650.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Prestige Biopharma's directors